Drug
Afm11
Afm11: highest development phase Phase 1, developed by Affimed. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Affimed
Trials
| Drug | Phase | Indication |
|---|---|---|
| AFM11 NCT02106091 | Phase 1 | Relapsed B-Cell Non-Hodgkin Lymphoma |
| AFM11 NCT02848911 | Phase 1 | Leukemia, B-Cell |
Latest
No recent events.
Follow Afm11 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.